# Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

> **NCT02948075** · PHASE2 · COMPLETED · sponsor: **NewVac LLC** · enrollment: 31 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Quisinostat
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02948075
- **Lead sponsor:** NewVac LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-12
- **Final completion:** 2017-06-16
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2018-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02948075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02948075, "Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02948075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*